Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SynKIR-110
i
Other names:
SynKIR-110, autologous T cells transduced with mesothelin KIR-CAR, SynKIR110, SynKIR 110
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
University of Pennsylvania, Verismo Therap
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
‹
MSLN-CAR-T cell therapy (3)
ATA3271 (2)
AB-1015 (0)
ATA2271 (0)
BZD1901 (0)
CD40 ligand expressing MSLN-CAR T (0)
GC008t (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LCAR-M23 (0)
LD013 (0)
MCY-M11 IP (0)
MPTK-CAR-T cells (0)
MSLN CAR-T (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB103 (0)
RD133 (0)
TmMSTN-01 (0)
UCARTMESO (0)
UCLM802 (0)
YTS105 (0)
anti- MESO CAR-T cells (0)
anti-mesothelin CAR T cells (0)
iCasp9M28z T cell infusion (0)
meso-CART (0)
mesothelin-targeted CAR-T immunotherapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
MSLN-CAR-T cell therapy (3)
ATA3271 (2)
AB-1015 (0)
ATA2271 (0)
BZD1901 (0)
CD40 ligand expressing MSLN-CAR T (0)
GC008t (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LCAR-M23 (0)
LD013 (0)
MCY-M11 IP (0)
MPTK-CAR-T cells (0)
MSLN CAR-T (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB103 (0)
RD133 (0)
TmMSTN-01 (0)
UCARTMESO (0)
UCLM802 (0)
YTS105 (0)
anti- MESO CAR-T cells (0)
anti-mesothelin CAR T cells (0)
iCasp9M28z T cell infusion (0)
meso-CART (0)
mesothelin-targeted CAR-T immunotherapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
›
Associations
(1)
News
Trials
Filter by
Latest
7d
Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies (clinicaltrials.gov)
P=N/A, N=0, Withdrawn, Verismo Therapeutics | N=100 --> 0 | Recruiting --> Withdrawn
7 days ago
Enrollment change • Trial withdrawal
|
SynKIR-110
3ms
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
P1, N=42, Recruiting, Verismo Therapeutics | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Dec 2027
3 months ago
Trial completion date • Trial primary completion date • Metastases
|
MSLN (Mesothelin)
|
SynKIR-110
7ms
Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies (clinicaltrials.gov)
P=N/A, N=100, Recruiting, Verismo Therapeutics
7 months ago
New trial
|
SynKIR-110
1year
Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma (SITC 2023)
These data support further clinical development of SynKIR-110 in patients with advanced solid tumors. SynKIR-110 is currently being investigated in a Phase I clinical trial STAR-101 (NCT05568680).
1 year ago
Preclinical • CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
MSLN positive
|
SynKIR-110
over1year
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
P1, N=42, Recruiting, Verismo Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023
over 1 year ago
Enrollment open • Trial initiation date • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
SynKIR-110
2years
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
P1, N=42, Not yet recruiting, Verismo Therapeutics
2 years ago
New P1 trial • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
SynKIR-110
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login